Omlyclo
Active substance: omalizumab
omalizumab
Centralised EU authorisationActive
Marketing holder: Celltrion Healthcare Hungary Kft.
Verified 2026-10-09 · EMA
Analogues in other countries- Source: EMA
- Countries with the substance registered: 3
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| RU 7 |
|
| US 11 |
|
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-54cf-79f9-86f9-b732d45e30ca,01a120c3-7e0c-7c41-af94-3feeb0d17808,01a120c3-db66-7c4b-a899-ece7f32f0a79,01a120c4-0a07-7d48-9840-d6b07c4f118d,01a120c5-bfd6-7083-b81f-5972735f2dcb;count=6 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-2cde-7bde-9607-43e39367a42f,01a1208c-cc95-7f18-a29a-08946090a10f,01a1208d-f7de-777d-a915-a5c0048e9fae,01a12091-b66e-7893-a58d-4dd7c8035971,01a12095-66b0-74cb-b854-d0a321cb8025;count=11 · valid from 2026-10-09 · verified 2026-10-09
- Registration number
- EMEA/H/C/005958
- Registration status
- Active
- ATC code
- R03DX05
- product · EMA · EMEA/H/C/005958 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/005958 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/005958 · Verified 2026-10-09